Mandate

Vinge advises Calliditas

Vinge advises Calliditas Therapeutics in connection with its capital raising and listing on The Nasdaq Global Select Market in United States.

The trading on The Nasdaq Global Select Market in United States began on 5 June 2020. The total value of the global offering amounts to approximately USD 103.5 million, assuming that the over allotment option is fully exercised.

Calliditas is a specialty pharmaceutical company, focused on the development and commercialization of the product candidate Nefecon, intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.

Vinge’s team consisted of Dain Hård Nevonen, Sofie Bjärtun, Nils Fredrik Dehlin, Hampus Olsson and Julia Hirschberg.

Related

Vinge advises Advania on the acquisition of Cortex Consult A/S

Vinge has advised Advania on the acquisition of Cortex Consult A/S, a Danish IT services company with more than 25 years of experience in managed IT services, cloud solutions and cybersecurity for customers across a range of industries.
August 18, 2026

Vinge advises Radonova Laboratories on the acquisition of the Norwegian company Skandinavisk Radoninvest

Radonova Laboratories, a subsidiary of the Lagercrantz Group, has acquired all the shares in the Norwegian company Skandinavisk Radoninvest. Both companies operate in the field of radon measurement.
August 14, 2026

Vinge has advised KLAR Partners in connection with its divestment of Swoosh Group to Serwent

Swoosh is a leading provider of inspection, maintenance, and services for underground infrastructure in Sweden, delivering sewer pipe inspection, cleaning, repair, and maintenance to municipalities, industrial operators, and property owners across 23 sites nationwide. Swoosh today employs approximately 450 people and generates revenues of nearly SEK 700 million.
August 13, 2026